Cargando…
Emerging pharmacotherapies for COVID-19
Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2...
Autores principales: | Salvi, Rachana, Patankar, Panini |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221369/ https://www.ncbi.nlm.nih.gov/pubmed/32410772 http://dx.doi.org/10.1016/j.biopha.2020.110267 |
Ejemplares similares
-
Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy
por: Heffernan, Kevin S., et al.
Publicado: (2020) -
Pharmacotherapy in COVID-19; A narrative review for emergency providers
por: Mehta, Nikita, et al.
Publicado: (2020) -
Current and Emerging Pharmacotherapy for Fibromyalgia
por: Tzadok, Roie, et al.
Publicado: (2020) -
Emerging Trend in the Pharmacotherapy of Osteoarthritis
por: Zhang, Wei, et al.
Publicado: (2019) -
Emerging Pharmacotherapies for Diabetic Macular Edema
por: Javey, Golnaz, et al.
Publicado: (2012)